Abstract
Aims: To determine the utility of FDG-PET in predicting long-term infield tumour control after RT in patients with metastatic hepatocellular carcinoma (HCC) to bone. Methods: Among 223 patients with HCC skeletal metastases diagnosed, we reviewed 22 patients with 45 total sites treated with RT who had at least two FDG-PETs prior to and after RT. The median RT dose was 42 Gy (range, 22-48) with a median fraction of 3 Gy (range, 2-8). Helical tomotherapy was generally offered for lesions that received higher RT dose (36%). The intrahepatic control rate in all patients was 73% at the time of referral. The ratio of tumour SUV to blood-pool activity SUV (SUV-ratio) was calculated. The primary end-points were infield progression-free survival (infield-PFS) and infield event-free survival (infield-EFS; recurrent and intractable pain or skeletal-related events). Results: Among 45 sites, 20 had tumour progression and 21 developed events in the previously treated area. A higher SUV-ratio before RT, SUV-ratio decline and higher radiation dose were independently and significantly correlated with better infield-PFS (both P < 0.05). The tumours with a pre-RT SUV-ratio ≥3.0 and SUV-ratio decline ≥40% had significantly better infield-PFS and EFS than those with either a pre-RT SUV-ratio <3.0 or SUV-ratio decline <40% (both P < 0.05). Conclusions: FDG-PET may help to predict outcomes of infield tumour control following palliative RT for treatment of HCC bone metastases. Tumours with low metabolic uptake before RT or with a minor decline in post-RT SUV-ratio showed poor long-term infield tumour control.
| Original language | English |
|---|---|
| Pages (from-to) | 1118-1125 |
| Number of pages | 8 |
| Journal | Liver International |
| Volume | 34 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - 2014 Jan 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Hepatology
Cite this
}
FDG-PET predicts outcomes of treated bone metastasis following palliative radiotherapy in patients with hepatocellular carcinoma. / Choi, Seo Hee; Chang, Jee Suk; Jeong, Yong Hyu; Lee, Youngin; Yun, Mijin; Seong, Jinsil.
In: Liver International, Vol. 34, No. 7, 01.01.2014, p. 1118-1125.Research output: Contribution to journal › Article
TY - JOUR
T1 - FDG-PET predicts outcomes of treated bone metastasis following palliative radiotherapy in patients with hepatocellular carcinoma
AU - Choi, Seo Hee
AU - Chang, Jee Suk
AU - Jeong, Yong Hyu
AU - Lee, Youngin
AU - Yun, Mijin
AU - Seong, Jinsil
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Aims: To determine the utility of FDG-PET in predicting long-term infield tumour control after RT in patients with metastatic hepatocellular carcinoma (HCC) to bone. Methods: Among 223 patients with HCC skeletal metastases diagnosed, we reviewed 22 patients with 45 total sites treated with RT who had at least two FDG-PETs prior to and after RT. The median RT dose was 42 Gy (range, 22-48) with a median fraction of 3 Gy (range, 2-8). Helical tomotherapy was generally offered for lesions that received higher RT dose (36%). The intrahepatic control rate in all patients was 73% at the time of referral. The ratio of tumour SUV to blood-pool activity SUV (SUV-ratio) was calculated. The primary end-points were infield progression-free survival (infield-PFS) and infield event-free survival (infield-EFS; recurrent and intractable pain or skeletal-related events). Results: Among 45 sites, 20 had tumour progression and 21 developed events in the previously treated area. A higher SUV-ratio before RT, SUV-ratio decline and higher radiation dose were independently and significantly correlated with better infield-PFS (both P < 0.05). The tumours with a pre-RT SUV-ratio ≥3.0 and SUV-ratio decline ≥40% had significantly better infield-PFS and EFS than those with either a pre-RT SUV-ratio <3.0 or SUV-ratio decline <40% (both P < 0.05). Conclusions: FDG-PET may help to predict outcomes of infield tumour control following palliative RT for treatment of HCC bone metastases. Tumours with low metabolic uptake before RT or with a minor decline in post-RT SUV-ratio showed poor long-term infield tumour control.
AB - Aims: To determine the utility of FDG-PET in predicting long-term infield tumour control after RT in patients with metastatic hepatocellular carcinoma (HCC) to bone. Methods: Among 223 patients with HCC skeletal metastases diagnosed, we reviewed 22 patients with 45 total sites treated with RT who had at least two FDG-PETs prior to and after RT. The median RT dose was 42 Gy (range, 22-48) with a median fraction of 3 Gy (range, 2-8). Helical tomotherapy was generally offered for lesions that received higher RT dose (36%). The intrahepatic control rate in all patients was 73% at the time of referral. The ratio of tumour SUV to blood-pool activity SUV (SUV-ratio) was calculated. The primary end-points were infield progression-free survival (infield-PFS) and infield event-free survival (infield-EFS; recurrent and intractable pain or skeletal-related events). Results: Among 45 sites, 20 had tumour progression and 21 developed events in the previously treated area. A higher SUV-ratio before RT, SUV-ratio decline and higher radiation dose were independently and significantly correlated with better infield-PFS (both P < 0.05). The tumours with a pre-RT SUV-ratio ≥3.0 and SUV-ratio decline ≥40% had significantly better infield-PFS and EFS than those with either a pre-RT SUV-ratio <3.0 or SUV-ratio decline <40% (both P < 0.05). Conclusions: FDG-PET may help to predict outcomes of infield tumour control following palliative RT for treatment of HCC bone metastases. Tumours with low metabolic uptake before RT or with a minor decline in post-RT SUV-ratio showed poor long-term infield tumour control.
UR - http://www.scopus.com/inward/record.url?scp=84904498362&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904498362&partnerID=8YFLogxK
U2 - 10.1111/liv.12487
DO - 10.1111/liv.12487
M3 - Article
VL - 34
SP - 1118
EP - 1125
JO - Liver International
JF - Liver International
SN - 1478-3223
IS - 7
ER -